CompletedNCT05613296
Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Principal Investigator
- Francesco ZajaEmatologia ASUGI Trieste
- Intervention
- Fostamatinib(drug)
- Enrollment
- 95 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2024
Study locations (21)
- AON SS. ANTONIO E BIAGIO E C. ARRIGO - SS emostasi e trombosi, Alessandria, Italy
- SOD Clinica Ematologica AOU Ospedali Riuniti Umberto I GM Lancisi G Salesi, Ancona, Italy
- UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro, Bari, Italy
- Istituto di Ematologia "Lorenzo e A. Seragnoli" Policlinico S. Orsola, Bologna, Italy
- Asst Degli Spedali Civili Di Brescia - Uo Ematologia, Brescia, Italy
- Unità di Onco-Ematologia - Azienda Ospedaliera Garibaldi, Catania, Italy
- Ematologia A.O.U. Careggi, Florence, Italy
- Milano Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia, Milan, Italy
- Ematologia AOU Università degli Studi di Napoli "Federico II", Naples, Italy
- .C.D.U. Ematologia - Università del Piemonte Orientale Amedeo Avogadro, Novara, Italy
- Aou Policlinico P. Giaccone Uo Ematologia, Palermo, Italy
- Casa Di Cura La Maddalena S.P.A. - Dipartimento Oncologico Di Iii Livello - Uo Oncoematologia E Tmo, Palermo, Italy
- Aou Pisana - Uo Ematologia Universitaria, Pisa, Italy
- S.C. di Ematologia, Arcispedale Santa Maria Nuova I.R.C.C.S., Reggio Emilia, Italy
- Aou Policlinico Tor Vergata Uoc Trapianto Cellule Staminali, Roma, Italy
- +6 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05613296 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation